Evolus Return on Tangible Equity 2016-2025 | EOLS
Current and historical return on tangible equity values for Evolus (EOLS) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Evolus Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-03-31 | $-0.06B | $-0.08B | 89.24% |
| 2024-12-31 | $-0.05B | $-0.06B | 89.69% |
| 2024-09-30 | $-0.06B | $-0.06B | 88.71% |
| 2024-06-30 | $-0.05B | $-0.05B | 77.66% |
| 2024-03-31 | $-0.06B | $-0.05B | 80.00% |
| 2023-12-31 | $-0.06B | $-0.09B | 79.23% |
| 2023-09-30 | $-0.06B | $-0.09B | 91.64% |
| 2023-06-30 | $-0.07B | $-0.08B | 115.28% |
| 2023-03-31 | $-0.07B | $-0.06B | 159.55% |
| 2022-12-31 | $-0.07B | $-0.05B | 246.67% |
| 2022-09-30 | $-0.08B | $-0.04B | 535.59% |
| 2022-06-30 | $-0.08B | $-0.02B | -4457.14% |
| 2022-03-31 | $-0.07B | $0.00B | -443.75% |
| 2021-12-31 | $-0.05B | $0.01B | -1105.88% |
| 2021-09-30 | $-0.14B | $0.03B | 394.37% |
| 2021-06-30 | $-0.13B | $0.03B | 251.43% |
| 2021-03-31 | $-0.14B | $-0.05B | 196.42% |
| 2020-12-31 | $-0.16B | $-0.15B | 265.04% |
| 2020-09-30 | $-0.07B | $-0.04B | 273.47% |
| 2020-06-30 | $-0.08B | $-0.04B | 278.99% |
| 2020-03-31 | $-0.10B | $-0.02B | 327.87% |
| 2019-12-31 | $-0.09B | $0.00B | 333.94% |
| 2019-09-30 | $-0.09B | $-0.06B | 348.51% |
| 2019-06-30 | $-0.07B | $-0.04B | 1536.84% |
| 2019-03-31 | $-0.05B | $-0.01B | 1073.68% |
| 2018-12-31 | $-0.05B | $0.01B | 471.79% |
| 2018-09-30 | $-0.03B | $0.02B | 60.30% |
| 2018-06-30 | $-0.02B | $-0.04B | 38.71% |
| 2018-03-31 | $-0.01B | $-0.03B | 15.73% |
| 2017-12-31 | $-0.01B | $-0.15B | 13.07% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.589B | $0.266B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $232.616B | 27.97 |
| Boston Scientific (BSX) | United States | $153.611B | 38.46 |
| Stryker (SYK) | United States | $149.817B | 31.33 |
| EssilorLuxottica (ESLOY) | France | $128.259B | 0.00 |
| Medtronic (MDT) | Ireland | $112.441B | 15.94 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.320B | 0.00 |
| Haleon (HLN) | United Kingdom | $45.596B | 26.03 |
| ResMed (RMD) | United States | $37.597B | 28.24 |
| GE HealthCare Technologies (GEHC) | United States | $34.163B | 16.22 |
| Agilent Technologies (A) | United States | $33.875B | 22.08 |
| Terumo (TRUMY) | Japan | $24.770B | 32.17 |
| Koninklijke Philips (PHG) | Netherlands | $22.956B | 16.11 |
| Insulet (PODD) | United States | $21.162B | 83.07 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.315B | 11.76 |
| Baxter (BAX) | United States | $15.236B | 11.38 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.113B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.723B | 23.40 |
| Lantheus Holdings (LNTH) | United States | $5.479B | 13.82 |
| Prestige Consumer Healthcare (PBH) | United States | $3.900B | 17.42 |
| Perrigo (PRGO) | Ireland | $3.676B | 9.32 |
| Haemonetics (HAE) | United States | $3.609B | 16.44 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.334B | 27.70 |
| ICU Medical (ICUI) | United States | $3.192B | 23.54 |
| QuidelOrtho (QDEL) | United States | $1.976B | 13.59 |
| LeMaitre Vascular (LMAT) | United States | $1.875B | 41.91 |
| AtriCure (ATRC) | United States | $1.561B | 0.00 |
| Acuren (TIC) | United States | $1.375B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.248B | 12.67 |
| Phibro Animal Health (PAHC) | United States | $1.212B | 15.49 |
| Green Thumb Industries (GTBIF) | United States | $1.163B | 26.16 |
| Neogen (NEOG) | United States | $1.081B | 13.83 |
| BioLife Solutions (BLFS) | United States | $1.036B | 0.00 |
| InMode (INMD) | Israel | $0.954B | 9.62 |
| Kestra Medical Technologies (KMTS) | United States | $0.757B | 0.00 |
| Owens & Minor (OMI) | United States | $0.669B | 5.55 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.662B | 0.00 |
| CeriBell (CBLL) | United States | $0.622B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.553B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.507B | 0.00 |
| Valneva SE (VALN) | France | $0.488B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.452B | 0.00 |
| Surmodics (SRDX) | United States | $0.424B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.360B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.344B | 12.67 |
| SNDL (SNDL) | Canada | $0.326B | 0.00 |
| Quanterix (QTRX) | United States | $0.315B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.284B | 0.00 |
| Cerus (CERS) | United States | $0.277B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.272B | 22.90 |
| ZimVie (ZIMV) | United States | $0.263B | 11.94 |
| Sanara MedTech (SMTI) | United States | $0.259B | 0.00 |
| Brainsway (BWAY) | Israel | $0.253B | 66.85 |
| Aurora Cannabis (ACB) | Canada | $0.249B | 73.83 |
| Cresco Labs (CRLBF) | United States | $0.247B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.228B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.221B | 0.00 |
| Biote (BTMD) | United States | $0.218B | 6.14 |
| TriSalus Life Sciences (TLSI) | United States | $0.188B | 0.00 |
| High Tide (HITI) | Canada | $0.188B | 0.00 |
| Organigram Global (OGI) | Canada | $0.186B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.186B | 15.13 |
| Omeros (OMER) | United States | $0.180B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.173B | 0.00 |
| Exagen (XGN) | United States | $0.148B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.147B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.129B | 15.90 |
| Apyx Medical (APYX) | United States | $0.098B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 12.37 |
| Jin Medical (ZJYL) | China | $0.090B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.088B | 0.00 |
| MacroGenics (MGNX) | United States | $0.086B | 0.00 |
| Veru (VERU) | United States | $0.086B | 0.00 |
| Zynex (ZYXI) | United States | $0.076B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.075B | 0.00 |
| Agape ATP (ATPC) | $0.070B | 0.00 | |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.062B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 58.29 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| Safety Shot (SHOT) | United States | $0.038B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.10 |
| Rockwell Medical (RMTI) | United States | $0.027B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |